Rigel Pharmaceuticals Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Rigel Pharmaceuticals Inc (RIGL) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Rigel Pharmaceuticals Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 277M vs 651M combined for its competitors (29.8% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+13.7% annualized vs trailing 12 months), vs decelerating (-8.8%) for its tracked peer group.
- Growth: Rigel Pharmaceuticals Inc generated -22.6% revenue growth year over year in Q2 2026, vs 14.0% for its competitors combined.
- Profitability: Its 22.0% net margin compares with -207.9% for the peer group.
- Scale: Rigel Pharmaceuticals Inc ranks #157 of 545 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 0.0% of industry market cap.
- Peer revenue share: Rigel Pharmaceuticals Inc accounted for 34.7% of combined revenue among its tracked peer group, down from 43.9% a year earlier.
- Peer differentiation: Revenue per employee of $1.59M compares with $0.46M for the peer group (3.5x).
- Structure: Rigel Pharmaceuticals Inc operates in the following segments: One Operating.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
RIGL Sales vs. its Competitors, Q2 2026
Rigel Pharmaceuticals Inc reported revenue contraction of 22.60 % year on year in Q2 2026, below its competitors' combined revenue growth of 14.02 %.
With a net margin of 21.97 %, Rigel Pharmaceuticals Inc achieved higher profitability than its competitors (-207.89 %).
Rigel Pharmaceuticals Inc generated 34.67 % of the combined sales of its peer group, down from 43.88 % a year earlier.
API endpoints for this dataset
Rigel Pharmaceuticals Inc vs. its Competitors, Q2 2026
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Rigel Pharmaceuticals Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Rigel Pharmaceuticals Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Rigel Pharmaceuticals Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (3) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (10) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (3) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Rigel Pharmaceuticals Inc's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 8.9% year over year, combined, vs -22.6% for Rigel Pharmaceuticals Inc. Rigel Pharmaceuticals Inc's share of combined industry revenue moved from 0.02% to 0.02%, a loss of 0.01 percentage points.
Rigel Pharmaceuticals Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Rigel Pharmaceuticals Inc | - | Yes | No | No |
| Competitors combined (19) | ||||
| High-Confidence Competitors (4) | ||||
| Similar-Size Competitors (10) | ||||
| Similar Growth & Profitability (8) | 100.00 % (8 of 8) | 87.50 % (7 of 8) | 50.00 % (4 of 8) | 12.50 % (1 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
RIGL Stock Performance relative to its Competitors
RIGL Stock Performance relative to High-Confidence Competitors
RIGL Stock Performance relative to Similar-Size Competitors
RIGL Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Erasca Inc | 282.9% | Outperformed |
| 2 | Iovance Biotherapeutics inc | 282.9% | Outperformed |
| 3 | Kezar Life Sciences Inc | 282.9% | Outperformed |
| 4 | Macrogenics Inc | 282.9% | Outperformed |
| 5 | Zymeworks Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Rigel Pharmaceuticals Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Rigel Pharmaceuticals Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Rigel Pharmaceuticals Inc |
775.95 | 276.79 |
 Hutchmed china Limited |
13,233.03 | 548.51 |
 Blueprint Medicines Corporation |
8,615.12 | 562.12 |
 Erasca Inc |
4,486.36 | - |
 Iovance Biotherapeutics inc |
3,619.52 | 324.97 |
 Zymeworks Inc |
2,162.79 | 37.13 |
| SUBTOTAL | 36,391.61 | 2,047.85 |
Sign in to see all competitors of Rigel Pharmaceuticals Inc.
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Rigel Pharmaceuticals Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Rigel Pharmaceuticals Inc's Competitors Named by the Company
Competitive relationships identified from Rigel Pharmaceuticals Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Nuvation Bio Inc | Company report | 85% |
| Sellas Life Sciences Group Inc | Company report | 85% |
| Curis Inc | Company report | 85% |
| Aptose Biosciences Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Rigel Pharmaceuticals Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Rigel Pharmaceuticals Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Rigel Pharmaceuticals Inc | One Operating 100.00 % |
| Hutchmed china Limited | Other Ventures segment 47.94 % |
| Blueprint Medicines Corporation | Single Reportable Segment 100.00 % |
| Iovance Biotherapeutics inc | Single reportable segment 100.00 % |
| Macrogenics Inc | Main 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Rigel Pharmaceuticals Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Rigel Pharmaceuticals Inc | 776 | 1,590,718 | 1,850,052 |
| Hutchmed china Limited | 13,233 | 703,221 | 586,836 |
| Blueprint Medicines Corporation | 8,615 | 965,844 | -267,576 |
| Erasca Inc | 4,486 | - | -2,788,573 |
| Iovance Biotherapeutics inc | 3,620 | 333,302 | -296,941 |
| Zymeworks Inc | 2,163 | 140,633 | -568,152 |
| PEERS TOTAL | 35,616 | 458,350 | -353,861 |
Sign in to see all peers for Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Hutchmed china Limited | CN 74.28 % |
| Iovance Biotherapeutics inc | US 98.66 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Rigel Pharmaceuticals Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 495 companies in Rigel Pharmaceuticals Inc's industry classification, broader than the peer set above. Market cap in millions of $.Rigel Pharmaceuticals Inc ranks #157 of 495 companies by market capitalization in its industry, holding 0.01 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 875, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,210,070 | 20.69 % |
| 2 | Johnson and Johnson | 674,004 | 11.53 % |
| 3 | Beone Medicines Ltd | 612,622 | 10.48 % |
| 4 | Abbvie Inc | 515,910 | 8.82 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Astrazeneca Plc | 1,234 | 5.2% |
| 157 | Rigel Pharmaceuticals Inc | 776 | 0.01 % |
Market cap and industry share for the rest of Rigel Pharmaceuticals Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-06.
Rigel Pharmaceuticals Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 152 | Annexon Inc | 844 | 35.22 % |
| 153 | Verastem Inc | 842 | -0.86 % |
| 154 | Collegium Pharmaceutical Inc | 786 | -32.91 % |
| 155 | Climb Bio Inc | 784 | 368.75 % |
| 156 | Lexicon Pharmaceuticals Inc | 1,234 | 12.3% |
| 157 | Rigel Pharmaceuticals Inc | 776 | 6.35 % |
| 158 | Alumis inc | 1,234 | 12.3% |
| 159 | Olema Pharmaceuticals Inc | 1,234 | 12.3% |
| 160 | Seaport Therapeutics Inc | 1,234 | 12.3% |
| 161 | Ironwood Pharmaceuticals inc | 1,234 | 12.3% |
| 162 | Arbutus Biopharma Corp | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Rigel Pharmaceuticals Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-06. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Rigel Pharmaceuticals Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (444 companies). See the full Major Pharmaceutical Preparations industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 91.39 % | 37.89 % (avg) | +53.5 pp |
| Operating Margin | 31.45 % | industry median | +32.1 pp |
| EBITDA Margin | 35.33 % | -6.23 % (avg) | +41.6 pp |
| Capital Intensity (Capex / Revenue) | 25.42 % | 7.58 % (avg) | +17.8 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Rigel Pharmaceuticals Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (444 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | 1.8x | 26.6x | -24.8x |
| EV / EBITDA | 6.2x | 15.9x | -9.7x |
| P/B | 1.8x | 4.3x | -2.4x |
| Return on Equity | 96.49 % | industry aggregate | 80.14 % |
| Return on Invested Capital | 12.52 % | -9.83 % (avg) | 22.35 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Rigel Pharmaceuticals Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | - | - | 83.21 % | 37.39 % | -19.43 % | -2.79 % | 53.38 % | 64.15 % |
| Operating Margin | - | -116.53 % | -26.67 % | -8.37 % | -46.20 % | -17.53 % | 13.49 % | 42.63 % |
| Return on Invested Capital | -38.75 % | -35.20 % | -19.30 % | -6.55 % | -100.42 % | -60.00 % | 39.79 % | 35.81 % |
| P/E | - | - | - | - | - | - | 19.6x | 1.9x |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Rigel Pharmaceuticals Inc's Strategic Group Map
Rigel Pharmaceuticals Inc is shown in red; its closest peers by combined growth, margin and ROIC are labeled. See Methodology: Strategic Group Map for how this chart is built.
Rigel Pharmaceuticals Inc's trailing-12-month revenue growth of 3.3% and operating margin of 31.5% compares with an average of 6.8% growth and 26.6% margin across its 8 closest peers by combined growth, margin and ROIC -- Rigel Pharmaceuticals Inc sits below that peer average on growth and above it on margin.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Rigel Pharmaceuticals Inc's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Rigel Pharmaceuticals Inc falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 8.2% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Rigel Pharmaceuticals Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 875 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | High (capital intensive) | Capital intensity (capex / revenue) of 25.42 % vs industry average 7.58 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Rigel Pharmaceuticals Inc's dedicated Suppliers and Customers pages, not here.
Rigel Pharmaceuticals Inc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Rigel Pharmaceuticals Inc falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Rigel Pharmaceuticals Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Operating margin 32.1 points above the industry median.
- Return on equity 80.1 points above the industry aggregate.
- Latest-quarter revenue run-rate is accelerating (+13.7% annualized vs trailing 12 months).
Weaknesses
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.00x).
Opportunities
- Trades at a lower P/E than the industry average (1.8x vs 26.6x) despite a higher return on invested capital -- a possible re-rating opportunity.
- A meaningful share of competitors (36.80 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-8.8% annualized).
- High capital intensity requires continuous reinvestment just to keep pace with the industry.
Methodology: see Methodology: SWOT Analysis.
Rigel Pharmaceuticals Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Rigel Pharmaceuticals Inc | 0.55 | 2.31 | 0.18 |
| Hutchmed china Limited | 0.23 | 4.96 | 0.10 |
| Blueprint Medicines Corporation | 0.36 | 3.16 | 2.48 |
| Erasca Inc | 4.90 | 9.52 | - |
| Iovance Biotherapeutics inc | 1.26 | 3.60 | 0.00 |
| Zymeworks Inc | 3.17 | 7.32 | - |
Sign in to see all peers for Rigel Pharmaceuticals Inc.
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Rigel Pharmaceuticals Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Rigel Pharmaceuticals Inc | Q2 2026 | -22.6 % | -71.0 % |
| Hutchmed china Limited | Q4 2025 | -13.0 % | +1,099.2 % |
| Blueprint Medicines Corporation | Q1 2025 | +55.5 % | -99.4 % |
| Erasca Inc | Q2 2026 | - | - |
| Iovance Biotherapeutics inc | Q2 2026 | +65.7 % | - |
| Zymeworks Inc | Q2 2026 | -90.6 % | - |
| PEERS TOTAL | -1.2 % | - |
Sign in to see all peers for Rigel Pharmaceuticals Inc.
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Rigel Pharmaceuticals Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Rigel Pharmaceuticals Inc | Q2 2026 | +89.3 % | - |
| Hutchmed china Limited | Q4 2025 | -3.6 % | -44.2 % |
| Blueprint Medicines Corporation | Q1 2025 | -12.2 % | +65.9 % |
| Erasca Inc | Q2 2026 | - | -73.3 % |
| Iovance Biotherapeutics inc | Q2 2026 | -10.8 % | -27.1 % |
| Zymeworks Inc | Q2 2026 | - | - |
Sign in to see all peers for Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Rigel Pharmaceuticals Inc | 72.27% | 89.00% | 96.49% |
| Hutchmed china Limited | 26.11% | 30.87% | 36.98% |
| Blueprint Medicines Corporation | - | - | - |
| Erasca Inc | - | - | - |
| Iovance Biotherapeutics inc | - | - | - |
| Zymeworks Inc | - | - | - |
Sign in to see all peers for Rigel Pharmaceuticals Inc.
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Rigel Pharmaceuticals Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Rigel Pharmaceuticals Inc | 2.33 | 2.80 |
| Hutchmed china Limited | 29.15 | 24.13 |
| Blueprint Medicines Corporation | - | 15.33 |
| Erasca Inc | - | - |
| Iovance Biotherapeutics inc | - | 11.14 |
| Zymeworks Inc | - | 58.25 |
| PEERS AVERAGE | - | 17.77 |
Sign in to see all peers for Rigel Pharmaceuticals Inc.
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.